MedPath
HSA Approval

NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML

SIN16393P

NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML

NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML

December 8, 2021

PHARMA TO MARKET PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantPHARMA TO MARKET PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

INJECTION, SOLUTION

SUBCUTANEOUS

Medical Information

L03AA13

pegfilgrastim

Manufacturer Information

PHARMA TO MARKET PTE. LTD.

Biocon Biologics India Limited

Active Ingredients

Pegfilgrastim

6mg/syringe

Pegfilgrastim

Documents

Package Inserts

1.4.3 NUFILONG LEAFLET SINGAPORE_NEW_revised Nov 2021.pdf

Approved: December 8, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

NUFILONG SOLUTION FOR INJECTION IN A PRE-FILLED SYRINGE 6MG/0.6ML - HSA Approval | MedPath